Simplify Logo
Jazz Pharmaceuticals

Jazz Pharmaceuticals

Biopharmaceuticals focused on neuroscience and oncology

Associate Director - Enterprise AI Architect

Full-Time
$153.6k - $230.4k/yr

+ Discretionary annual cash bonus + Discretionary equity grants

Mid, Senior
Bachelor's, Master's, PhD
Pennsylvania, USA
Remote

Residency in Pennsylvania required.

About the job

Requirements
  • Strong communication skills with clear ability to communicate complex AI concepts to business leaders at all levels
  • Familiarity with AI governance and risk frameworks
  • Deep knowledge of AI/ML system architecture, including data pipelines, model development and deployment patterns, cloud-based ML infrastructure, and integration of AI solutions into enterprise systems
  • Proficiency with MLOps concepts, tools, and best practices, such as CI/CD, model versioning, experiment tracking, and monitoring (enabling reliable ML production deployments)
  • Strong understanding of core machine learning algorithms and statistical modeling techniques, model evaluation, and real-world deployment considerations
  • Proficiency in one or more programming languages (e.g. Python, R) and ML frameworks (such as TensorFlow, PyTorch, scikit-learn)
  • Strong understanding of modern Generative AI concepts and approaches: LLMs, Retrieval-Augmented Generation, fine-tuning, agentic patterns, evaluation, and guardrails
  • Significant hands-on experience with at least one major cloud platform (AWS, GCP, or Azure); AWS or GCP preferred
  • Bachelor’s degree or equivalent practical experience in a quantitative or technical field; Advanced degree preferred
  • 5–7 years of relevant AI, machine learning, or data science experience; 10+ years preferred
  • Experience in pharmaceutical, life sciences, or another regulated industry strongly preferred
  • Experience evaluating and integrating third-party AI/ML solutions and vendor platforms strongly preferred
Responsibilities
  • Define and continuously enhance Jazz’s enterprise AI/ML architecture strategy, working with senior Data & AI leadership to align technology stack, operating models, governance frameworks, best practices, and policies with enterprise objectives
  • Establish AI architectural standards and reference architectures that ensure consistency, scalability, and security across all AI/ML initiatives
  • Establish and maintain AI governance processes and architectural guardrails, including guidelines for responsible AI use, model validation, risk management, and regulatory compliance, to ensure safe and ethical use of AI technologies in line with Jazz’s standards
  • Drive adoption of responsible AI practices (e.g. explainability, bias mitigation, data privacy protection) across the organization
  • Provide architectural oversight and technical guidance on AI/ML solution design and integration. Define overarching Enterprise AI architecture standards
  • Conduct architectural reviews and advise project teams on end-to-end AI/ML solution design – from data ingestion and model development to deployment, monitoring, and MLOps – ensuring solutions are robust, scalable, and aligned with enterprise data, security, and compliance standards
  • Serve as a subject-matter expert (SME) and trusted advisor on AI/ML architecture across technology teams
  • Evaluate and design AI/ML and Generative AI solutions, ensuring proposed approaches meet enterprise architectural standards and align with strategic goals. Challenge technical designs and assumptions to uphold Jazz’s requirements for reliable, compliant, and maintainable AI solutions
  • Contribute to discussions on AI use case priority using expertise in AI architecture to advise on feasibility, scalability, reliability, and how to avoid technical debt
  • Vet AI vendors and platforms in collaboration with our AI Development Lead, as well as Infrastructure and Digital Security teams. Together, conduct technical due diligence on solution feasibility, data handling, security, transparency, and overall operational maturity. During such evaluations, this role will focus on the proposed architecture viability and quality
  • Build credibility quickly with senior technical and business stakeholders through effective communication and deep expertise
  • Communicate complex architecture decisions and technical concepts in clear, business-relevant terms, and influence decision-making in cross-functional governance forums to align AI efforts with business objectives

About the company

Jazz Pharmaceuticals develops and markets therapies in neuroscience and oncology. Its products include Xyrem and the lower-sodium option Xywav for narcolepsy, Epidiolex for seizures in severe epilepsy, and oncology medicines Zepzelca for small cell lung cancer and Vyxeos for AML, with Epidiolex being cannabidiol-based. The company grows its portfolio through a mix of in-house R&D and strategic acquisitions that broaden its specialty-drug lineup and global reach. Its goal is to expand approved treatments and the pipeline to help patients with limited options by building a diversified, specialty-focused portfolio.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Dublin, Ireland

Founded

2003

Get referred to Jazz Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ziihera's August 2026 FDA win expands Jazz into a $3 billion-to-$5 billion opportunity.
  • Q2 2026 revenue reached $1.21 billion, and guidance rose to $4.60 billion-$4.75 billion.
  • Actio Biosciences acquisition closed September 15, 2026, adding KCNT1+ epilepsy upside.

What critics are saying

  • Tris Pharma filed generic Xywav and Xyrem applications in January 2026, threatening 2027 pricing.
  • Long-term debt was $4.4 billion at June 30, 2026, limiting flexibility for pipeline deals.
  • Zepzelca's failed second-line SCLC trial narrows growth if first-line maintenance adoption slows.

What makes Jazz Pharmaceuticals unique

  • Xywav's low-sodium profile keeps narcolepsy and idiopathic hypersomnia patients on therapy.
  • Ziihera became Jazz's first FDA-approved HER2-targeted backbone for first-line GEA on August 25, 2026.
  • Jazz combines rare sleep, epilepsy, and oncology commercialization across one scaled specialty platform.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Paid Vacation

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

0%
Yahoo Finance
Sep 11th, 2026
Jazz Pharmaceuticals stock climbs 29.7% but analysts warn of declining margins and weak returns

Jazz Pharmaceuticals' stock has risen 29.7% over the past six months, outpacing the S&P 500 by 17 percentage points to reach $240.49 per share. However, analysts point to concerning trends in the company's fundamentals. The company's adjusted operating margin has declined by 2.6 percentage points over five years, despite revenue growth that should have improved economies of scale. Its trailing 12-month adjusted operating margin stood at 41.7%. Additionally, Jazz Pharmaceuticals' five-year average return on invested capital was just 2.7%, below the typical cost of capital for healthcare companies. This suggests mediocre efficiency in deploying capital for growth. The stock currently trades at 9.6× forward price-to-earnings ratio. Analysts consider this valuation reasonable but believe the company's weakening fundamentals present downside risk.

StockTitan
Aug 27th, 2026
Jazz Pharmaceuticals prices upsized $1.1B exchangeable notes offering with $225M share repurchase

Jazz Pharmaceuticals has priced an upsized $1.1 billion private offering of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion. The offering, conducted through its wholly-owned subsidiary Jazz Investments I Limited, is expected to close on 31 August 2026. The notes will mature on 15 September 2032 and are exchangeable at an initial rate of 2.8150 ordinary shares per $1,000 principal amount, equivalent to an exchange price of approximately $355.24 per share. This represents a 42.5% premium above the last reported sale price on 26 August 2026. The company will use net proceeds of approximately $1,079 million for general corporate purposes. Concurrently, Jazz Pharmaceuticals agreed to repurchase approximately $225 million of its ordinary shares from note purchasers at $249.29 per share, using existing cash on hand.

Yahoo Finance
Aug 26th, 2026
Jazz Pharmaceuticals launches Ziihera for HER2-positive cancer with $3B–$5B peak sales outlook

Jazz Pharmaceuticals has launched Ziihera in the US following FDA approval for first-line treatment of HER2-positive, unresectable or metastatic gastroesophageal adenocarcinoma. The drug can be used with tislelizumab and chemotherapy, or with chemotherapy alone for certain patients. In the Phase III HERIZON-GEA-01 trial, Ziihera-based regimens reduced the risk of disease progression or death by 35%. The triplet regimen extended median overall survival to 26.4 months, a 28% reduction in death risk versus trastuzumab. Jazz estimates the US addressable market at 3,000–4,000 patients annually and raised Ziihera's peak sales outlook to $3 billion–$5 billion. The company plans to leverage existing commercial infrastructure whilst pursuing additional cancer indications and international regulatory filings.

Yahoo Finance
Aug 11th, 2026
Jazz Pharmaceuticals Q2 revenue beats estimates at $1.21B, ups guidance to $4.68B

Jazz Pharmaceuticals reported a strong second quarter with revenue of $1.21 billion, beating analyst estimates of $1.12 billion and representing 15.5% year-on-year growth. The company raised its full-year revenue guidance to $4.68 billion from $4.38 billion. CEO Renée Galá attributed the performance to strong demand for flagship products like Xywav and Epidiolex, alongside accelerating uptake of new oncology therapies. Operating margin improved to 20.5%, up from negative 65.6% in the prior year quarter. However, adjusted earnings per share of $5.71 missed analyst expectations of $6.18. During the earnings call, analysts focused on Epidiolex's growth drivers, Xywav's sustainability amid potential generic competition, and zanidatamab's upcoming approval prospects.

Yahoo Finance
Aug 11th, 2026
Jazz Pharma raises 2026 guidance on record Q2 revenue of $1.2B, up 16%

Jazz Pharmaceuticals reported record second quarter revenue of $1.2 billion, representing 16% year-over-year growth. The company raised its full-year revenue guidance based on strong first-half performance. Chief executive officer Renée Galá attributed the results to execution across the company's diversified portfolio and sustained demand for its commercial products. The company is preparing to launch zanidatamab, with a PDUFA date of 25 August for treatment of first-line HER2-positive metastatic gastroesophageal adenocarcinoma. The earnings call included updates from senior leadership, including chief commercial officer Samantha Pearce, global head of research and development Robert Iannone, and chief financial officer Philip Johnson. Jazz Pharmaceuticals highlighted progress on its long-term value creation priorities whilst maintaining focus on current commercial operations.